Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.